The US Senate has moved forward with the Genius Act, a bill designed to regulate stablecoins. Despite Democratic concerns ...

Deutsche Bank AG boosted its stake in Regeneron Pharmaceuticals by nearly 22% in Q4, now holding 539,269 shares valued at ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against Billionaire Mario Gabelli’s other large-cap stock picks with huge upside potential.

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective reduced by Truist Financial from $975.00 to $940.00 in a research note released on Wednesday,Benzinga reports.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 5.25% to $598.76 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX ...

The Italian Brainrot takes its cue from the Anglo-Saxon-derived English idiom "brain rot." Literally, it can be translated as "rotting brain" or "brain decay." But in internet parlance, it is used ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $8.22 EPS ...

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

A parallel universe where politicians are not in control but are definitely centre stage: The unpredictable, wildly entertaining world of memes, viral clips and cheeky online banter. Over the last ...

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...